Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds

FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling